Les complications sont rares, la plupart des cas étant asymptomatiques et sans incidents.
FréquenceComplications
#5
Y a-t-il des complications post-chirurgicales ?
Oui, des complications comme des infections ou des saignements peuvent survenir après la chirurgie.
ChirurgieComplications post-opératoires
Facteurs de risque
5
#1
Quels sont les principaux facteurs de risque ?
Les facteurs de risque ne sont pas bien définis, mais des antécédents familiaux peuvent être impliqués.
Facteurs de risqueAntécédents familiaux
#2
L'exposition à des toxines augmente-t-elle le risque ?
Aucune preuve solide ne lie l'exposition à des toxines au développement de l'hémangiome sclérosant.
ToxinesRisque
#3
Les antécédents médicaux influencent-ils le risque ?
Les antécédents médicaux ne semblent pas avoir d'impact direct sur le développement de cette tumeur.
Antécédents médicauxRisque
#4
Le tabagisme est-il un facteur de risque ?
Le lien entre tabagisme et hémangiome sclérosant n'est pas clairement établi dans la littérature.
TabagismeRisque
#5
Les facteurs génétiques jouent-ils un rôle ?
Des études suggèrent que des facteurs génétiques peuvent influencer le développement de l'hémangiome.
Facteurs génétiquesHémangiome
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Hémangiome sclérosant du poumon : Questions médicales les plus fréquentes",
"headline": "Hémangiome sclérosant du poumon : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Hémangiome sclérosant du poumon : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-17",
"dateModified": "2025-04-13",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Hémangiome sclérosant du poumon"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Tumeurs du poumon",
"url": "https://questionsmedicales.fr/mesh/D008175",
"about": {
"@type": "MedicalCondition",
"name": "Tumeurs du poumon",
"code": {
"@type": "MedicalCode",
"code": "D008175",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C08.785.520"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Hémangiome sclérosant du poumon",
"alternateName": "Pulmonary Sclerosing Hemangioma",
"code": {
"@type": "MedicalCode",
"code": "D047868",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Weidong Zhang",
"url": "https://questionsmedicales.fr/author/Weidong%20Zhang",
"affiliation": {
"@type": "Organization",
"name": "Department of Cardiothoracic Surgery, Henan Provincial Chest Hospital (Chest Hospital of Zhengzhou University), Zhengzhou, Henan, China. zhangweidong0371@126.com."
}
},
{
"@type": "Person",
"name": "Tae Wook Kang",
"url": "https://questionsmedicales.fr/author/Tae%20Wook%20Kang",
"affiliation": {
"@type": "Organization",
"name": "From the Department of Radiology and Center for Imaging Science, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul."
}
},
{
"@type": "Person",
"name": "Dong Ik Cha",
"url": "https://questionsmedicales.fr/author/Dong%20Ik%20Cha",
"affiliation": {
"@type": "Organization",
"name": "From the Department of Radiology and Center for Imaging Science, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul."
}
},
{
"@type": "Person",
"name": "Seong Hyun Kim",
"url": "https://questionsmedicales.fr/author/Seong%20Hyun%20Kim",
"affiliation": {
"@type": "Organization",
"name": "From the Department of Radiology and Center for Imaging Science, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul."
}
},
{
"@type": "Person",
"name": "Dan Song",
"url": "https://questionsmedicales.fr/author/Dan%20Song",
"affiliation": {
"@type": "Organization",
"name": "Department of Vascular Anomalies and Interventional Radiology, Jinan Children's Hospital, Qilu Children's Hospital of Shandong University, Jinan, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Radiographic Contrast Media and the Kidney.",
"datePublished": "2022-07-01",
"url": "https://questionsmedicales.fr/article/35777831",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.2215/CJN.16311221"
}
},
{
"@type": "ScholarlyArticle",
"name": "[Contrast Media Toxicity and Its Prevention].",
"datePublished": "2023-10-26",
"url": "https://questionsmedicales.fr/article/38010244",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": null
}
},
{
"@type": "ScholarlyArticle",
"name": "Contrast media volume reduction with the DyeVert",
"datePublished": "2023-09-05",
"url": "https://questionsmedicales.fr/article/37668067",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/ccd.30809"
}
},
{
"@type": "ScholarlyArticle",
"name": "Iodinated Contrast Media Conservation Measures During a Global Shortage: Effect on Contrast Media Use at a Large Health System.",
"datePublished": "2022-06-22",
"url": "https://questionsmedicales.fr/article/35731095",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.2214/AJR.22.28080"
}
},
{
"@type": "ScholarlyArticle",
"name": "Strategies for calculating contrast media dose for chest CT.",
"datePublished": "2023-06-12",
"url": "https://questionsmedicales.fr/article/37303003",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1186/s41747-023-00345-w"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Maladies de l'appareil respiratoire",
"item": "https://questionsmedicales.fr/mesh/D012140"
},
{
"@type": "ListItem",
"position": 3,
"name": "Tumeurs de l'appareil respiratoire",
"item": "https://questionsmedicales.fr/mesh/D012142"
},
{
"@type": "ListItem",
"position": 4,
"name": "Tumeurs du poumon",
"item": "https://questionsmedicales.fr/mesh/D008175"
},
{
"@type": "ListItem",
"position": 5,
"name": "Hémangiome sclérosant du poumon",
"item": "https://questionsmedicales.fr/mesh/D047868"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Hémangiome sclérosant du poumon - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Hémangiome sclérosant du poumon",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-09",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Hémangiome sclérosant du poumon",
"description": "Comment diagnostique-t-on un hémangiome sclérosant du poumon ?\nQuels examens sont recommandés pour confirmer le diagnostic ?\nLes symptômes influencent-ils le diagnostic ?\nPeut-on confondre cette tumeur avec d'autres lésions ?\nQuel rôle joue la biopsie dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D047868?mesh_terms=Contrast+Media#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Hémangiome sclérosant du poumon",
"description": "Quels sont les symptômes courants de l'hémangiome sclérosant ?\nL'hémangiome sclérosant cause-t-il des difficultés respiratoires ?\nPeut-on avoir des symptômes sans lésion visible ?\nLes symptômes varient-ils selon l'âge ?\nY a-t-il des symptômes spécifiques à surveiller ?",
"url": "https://questionsmedicales.fr/mesh/D047868?mesh_terms=Contrast+Media#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Hémangiome sclérosant du poumon",
"description": "Peut-on prévenir l'hémangiome sclérosant du poumon ?\nY a-t-il des facteurs de risque connus ?\nLes habitudes de vie influencent-elles le risque ?\nLes examens réguliers aident-ils à la détection précoce ?\nLes femmes sont-elles plus à risque ?",
"url": "https://questionsmedicales.fr/mesh/D047868?mesh_terms=Contrast+Media#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Hémangiome sclérosant du poumon",
"description": "Quel est le traitement standard pour l'hémangiome sclérosant ?\nPeut-on traiter cette condition par des médicaments ?\nQuand est-il nécessaire de surveiller sans traiter ?\nQuels sont les risques associés à la chirurgie ?\nY a-t-il des traitements alternatifs ?",
"url": "https://questionsmedicales.fr/mesh/D047868?mesh_terms=Contrast+Media#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Hémangiome sclérosant du poumon",
"description": "Quelles complications peuvent survenir ?\nL'hémangiome peut-il se transformer en cancer ?\nComment gérer les complications respiratoires ?\nLes complications sont-elles fréquentes ?\nY a-t-il des complications post-chirurgicales ?",
"url": "https://questionsmedicales.fr/mesh/D047868?mesh_terms=Contrast+Media#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Hémangiome sclérosant du poumon",
"description": "Quels sont les principaux facteurs de risque ?\nL'exposition à des toxines augmente-t-elle le risque ?\nLes antécédents médicaux influencent-ils le risque ?\nLe tabagisme est-il un facteur de risque ?\nLes facteurs génétiques jouent-ils un rôle ?",
"url": "https://questionsmedicales.fr/mesh/D047868?mesh_terms=Contrast+Media#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostique-t-on un hémangiome sclérosant du poumon ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'imagerie, notamment la tomodensitométrie (TDM) et la biopsie."
}
},
{
"@type": "Question",
"name": "Quels examens sont recommandés pour confirmer le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "La TDM thoracique et l'IRM peuvent aider à visualiser la lésion et son caractère bénin."
}
},
{
"@type": "Question",
"name": "Les symptômes influencent-ils le diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent être absents, rendant le diagnostic souvent incident lors d'examens pour d'autres raisons."
}
},
{
"@type": "Question",
"name": "Peut-on confondre cette tumeur avec d'autres lésions ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut être confondue avec d'autres tumeurs pulmonaires, nécessitant une analyse approfondie."
}
},
{
"@type": "Question",
"name": "Quel rôle joue la biopsie dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "La biopsie permet de confirmer la nature bénigne de la lésion et d'exclure d'autres pathologies."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants de l'hémangiome sclérosant ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Souvent asymptomatique, il peut provoquer une toux ou des douleurs thoraciques dans certains cas."
}
},
{
"@type": "Question",
"name": "L'hémangiome sclérosant cause-t-il des difficultés respiratoires ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Rarement, mais des complications peuvent entraîner des difficultés respiratoires dans certains cas."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des symptômes sans lésion visible ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes peuvent survenir sans lésion visible, rendant le diagnostic plus complexe."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon l'âge ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes ne varient pas significativement selon l'âge, car la plupart des cas sont asymptomatiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques à surveiller ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Surveillez la toux persistante ou des douleurs thoraciques, bien que souvent asymptomatique."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir l'hémangiome sclérosant du poumon ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de mesures préventives spécifiques pour cette condition bénigne."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs de risque connus ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs de risque ne sont pas clairement établis, mais des antécédents familiaux peuvent jouer un rôle."
}
},
{
"@type": "Question",
"name": "Les habitudes de vie influencent-elles le risque ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Aucune preuve directe ne lie les habitudes de vie au développement de l'hémangiome sclérosant."
}
},
{
"@type": "Question",
"name": "Les examens réguliers aident-ils à la détection précoce ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des examens réguliers peuvent aider à détecter des anomalies, mais l'hémangiome est souvent asymptomatique."
}
},
{
"@type": "Question",
"name": "Les femmes sont-elles plus à risque ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines études suggèrent une prévalence plus élevée chez les femmes, mais les données sont limitées."
}
},
{
"@type": "Question",
"name": "Quel est le traitement standard pour l'hémangiome sclérosant ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement est généralement chirurgical si la tumeur est symptomatique ou suspecte."
}
},
{
"@type": "Question",
"name": "Peut-on traiter cette condition par des médicaments ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de traitement médicamenteux spécifique, la chirurgie est la principale option."
}
},
{
"@type": "Question",
"name": "Quand est-il nécessaire de surveiller sans traiter ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Si la tumeur est asymptomatique et bénigne, une surveillance régulière peut suffire."
}
},
{
"@type": "Question",
"name": "Quels sont les risques associés à la chirurgie ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les risques incluent des infections, des saignements et des complications respiratoires post-opératoires."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements alternatifs ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements alternatifs ne sont pas prouvés efficaces et ne remplacent pas la chirurgie."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des infections pulmonaires et des hémorragies dans de rares cas."
}
},
{
"@type": "Question",
"name": "L'hémangiome peut-il se transformer en cancer ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, l'hémangiome sclérosant est une tumeur bénigne et ne se transforme pas en cancer."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications respiratoires ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications respiratoires doivent être traitées symptomatiquement et surveillées attentivement."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles fréquentes ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications sont rares, la plupart des cas étant asymptomatiques et sans incidents."
}
},
{
"@type": "Question",
"name": "Y a-t-il des complications post-chirurgicales ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications comme des infections ou des saignements peuvent survenir après la chirurgie."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs de risque ne sont pas bien définis, mais des antécédents familiaux peuvent être impliqués."
}
},
{
"@type": "Question",
"name": "L'exposition à des toxines augmente-t-elle le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Aucune preuve solide ne lie l'exposition à des toxines au développement de l'hémangiome sclérosant."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux influencent-ils le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents médicaux ne semblent pas avoir d'impact direct sur le développement de cette tumeur."
}
},
{
"@type": "Question",
"name": "Le tabagisme est-il un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le lien entre tabagisme et hémangiome sclérosant n'est pas clairement établi dans la littérature."
}
},
{
"@type": "Question",
"name": "Les facteurs génétiques jouent-ils un rôle ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études suggèrent que des facteurs génétiques peuvent influencer le développement de l'hémangiome."
}
}
]
}
]
}
Department of Vascular Anomalies and Interventional Radiology, Jinan Children's Hospital, Qilu Children's Hospital of Shandong University, Jinan, China.
Publications dans "Hémangiome sclérosant du poumon" :
Department of Vascular Anomalies and Interventional Radiology, Jinan Children's Hospital, Qilu Children's Hospital of Shandong University, Jinan, China.
Publications dans "Hémangiome sclérosant du poumon" :
Department of Vascular Anomalies and Interventional Radiology, Jinan Children's Hospital, Qilu Children's Hospital of Shandong University, Jinan, China.
Publications dans "Hémangiome sclérosant du poumon" :
Department of Vascular Anomalies and Interventional Radiology, Jinan Children's Hospital, Qilu Children's Hospital of Shandong University, Jinan, China.
Publications dans "Hémangiome sclérosant du poumon" :
Department of Vascular Anomalies and Interventional Radiology, Jinan Children's Hospital, Qilu Children's Hospital of Shandong University, Jinan, China.
Publications dans "Hémangiome sclérosant du poumon" :
Department of Vascular Anomalies and Interventional Radiology, Jinan Children's Hospital, Qilu Children's Hospital of Shandong University, Jinan, China.
Publications dans "Hémangiome sclérosant du poumon" :
AKI is a potential complication of intravascular iodinated contrast exposure. Contrast-associated AKI, which typically manifests as small and transient decrements in kidney function that develop withi...
Intravenous iodinated contrast media are commonly used in clinical practice, ranging from medical imaging to interventional radiology (IR) procedures and endovascular interventions. Compared with pati...
Contrast associated acute kidney injury (CA-AKI) can lead to an increased risk of adverse events. Contrast media (CM) volume reduction has been advocated as a pivotal strategy to prevent CA-AKI in sta...
To compare the effectiveness of CM volume reduction with the DyeVert...
We prospectively collected data from 136 patients with stable coronary artery disease at high risk of CA-AKI treated with left ventricular end diastolic pressure (LVEDP)- guided hydration and undergoi...
Patients in the DyeVert group were treated with a significant lower CM volume (median: 47.5 vs. 84.0 mL, p < 0.001). The trend in creatinine increase was lower (p = 0.004) and the Δ of creatinine (0-4...
CM volume reduction with the DyeVert...
The aim of this study was to quantify the effect of iodinated contrast media (ICM) conservation measures implemented at a single health system during a global shortage, comparing the 12-month period b...
Total body weight (TBW) is a frequently used contrast media (CM) strategy for dose calculation in enhanced CT, yet it is suboptimal as it lacks consideration of patient characteristics, such as body f...
Eighty-nine adult patients referred for CM thoracic CT were retrospectively included, categorized as either normal, muscular, or overweight. Patient body composition data was used to calculate the CM ...
BIA demonstrated the highest and lowest calculated CM dose in muscular and overweight groups respectively, compared to other strategies. For the normal group, the lowest calculated CM dose was achieve...
The BIA method is more adaptive to variations in patient body habitus especially in muscular and overweight patients and is most closely correlated to patient demographics. This study could support ut...
The BIA-based method is adaptive to variations in body habitus especially in muscular and overweight patients and is closely correlated to patient demographics for contrast-enhanced chest CT....
• Calculations based on BIA showed the largest variation in CM dose. • Lean body weight using BIA demonstrated the strongest correlation to patient demographics. • Lean body weight BIA protocol may be...
A severe shortage of iodinated contrast medium (ICM) has forced radiology departments around the world to implement strategies to reduce contrast utilization. The aim of this study was to evaluate the...
Our radiology department instituted several ICM-conserving interventions on 13...
The average daily number of CECT (all), CECT (inpatient and ED), CTPA, CECT AP, and 'Code stroke' CT scans decreased significantly (P < 0.01), by 58.6%, 68.8%, 74.1%, 88.0%, and 37.5%, respectively. T...
Interventions in CT alone, focused on improving patient triage to CECT while avoiding deferment of any outpatient oncology studies, have achieved an approximately two-thirds reduction in ICM consumpti...
To identify the risk factors for moderate and severe contrast media extravasation and provide effective guidance to reduce the degree of extravasation injuries....
We observed 224 adult patients who underwent contrast media extravasation at Xiangya Hospital of Central South University, Hunan Provincial Maternal and Child Healthcare Hospital, and Xiangya Changde ...
Among 224 patients, 0 (0%) had severe, 18 (8.0%) had moderate, and 206 (92.0%) had mild contrast media extravasation injury. Multivariate logistic regression analysis revealed malignant tumors (odds r...
Risk factors for moderate contrast media extravasation injury are malignant tumors, iohexol, large-volume (> 50 mL) extravasation, and back-of-the-hand injection. Analysis of these risk factors can he...
High-risk patients with extravasation support should choose the appropriate contrast media type, avoiding back-of-the-hand injections. We recommend that patients with cancer be implanted with a high-p...
Iodinated- (ICM) and gadolinium-based (GCM) contrast media are used in radiology imaging techniques, such as computer tomography (CT) and magnetic resonance (MR), respectively. The paper aims to analy...
To assess the role of atorvastatin to the frequency of contrast-induced acute kidney injury (CI-AKI) in patients with cardiovascular diseases (CVD) undergoing computed tomography (CT) with intravenous...
One hundred patients with CVD undergoing CT with with intravenous contrast media administration were included in prospective observational study (ClinicalTrials.gov ID NCT04666389). Patients were divi...
CI-AKI was diagnosed in 4 (3.96%) patients. At the same time, it was not possible to establish statistically significant relationships (p0.05) between risk factors and the development of CI-AKI. Stati...
Cardiovascular diseases may increase the risk of CI-AKI after computed tomography with intravenous contrast media administration. Therefore, it is recommended to evaluate the serum creatinine concentr...
To pool and summarise published data of pulmonary blood flow (PBF), pulmonary blood volume (PBV) and mean transit time (MTT) of the human lung, obtained with perfusion MRI or CT to provide reliable re...
PubMed was systematically searched to identify studies that quantified PBF/PBV/MTT in the human lung by injection of contrast agent, imaged by MRI or CT. Only data analysed by 'indicator dilution theo...
PBV was obtained from 313 measurements from 14 publications (wM: 13.97 ml/100 ml, wSD: 4.21 ml/100 ml, wCoV 0.30). MTT was obtained from 188 measurements from 10 publications (wM: 5.91 s, wSD: 1.84 s ...
Reference values for PBF, MTT and PBV were obtained in HV. The literature data are insufficient to draw strong conclusions regarding disease reference values....